JP2011500570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500570A5 JP2011500570A5 JP2010528917A JP2010528917A JP2011500570A5 JP 2011500570 A5 JP2011500570 A5 JP 2011500570A5 JP 2010528917 A JP2010528917 A JP 2010528917A JP 2010528917 A JP2010528917 A JP 2010528917A JP 2011500570 A5 JP2011500570 A5 JP 2011500570A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- dantrolene sodium
- solution
- group
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003710 dantrolene sodium Drugs 0.000 claims 21
- LTWQNYPDAUSXBC-CDJGKPBYSA-L dantrolene sodium hemiheptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1.C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)[N-]C(=O)C1 LTWQNYPDAUSXBC-CDJGKPBYSA-L 0.000 claims 21
- 229940079593 drug Drugs 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 16
- 239000000243 solution Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 8
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 7
- 229940091173 hydantoin Drugs 0.000 claims 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229940127003 anti-diabetic drug Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000012931 lyophilized formulation Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000012670 alkaline solution Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 229910052739 hydrogen Chemical group 0.000 claims 2
- 239000001257 hydrogen Chemical group 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 239000006166 lysate Substances 0.000 claims 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020844 Hyperthermia malignant Diseases 0.000 claims 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 claims 1
- 102000003982 Parathyroid hormone Human genes 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000003470 adrenal cortex hormone Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 229940070021 anabolic steroids Drugs 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- 229940124339 anthelmintic agent Drugs 0.000 claims 1
- 239000000921 anthelmintic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000001362 anti-vertigo Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940125713 antianxiety drug Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 239000002968 autonomic agent Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003183 carcinogenic agent Substances 0.000 claims 1
- 239000000496 cardiotonic agent Substances 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960001987 dantrolene Drugs 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940005494 general anesthetics Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 201000007004 malignant hyperthermia Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- -1 p-cyanophenyl Chemical group 0.000 claims 1
- 239000000199 parathyroid hormone Substances 0.000 claims 1
- 229960001319 parathyroid hormone Drugs 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940000045 sensory organ drug Drugs 0.000 claims 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims 1
- KSRLIXGNPXAZHD-HAZZGOGXSA-M sodium;3-[(e)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-5-oxo-4h-imidazol-2-olate Chemical compound [Na+].[O-]C1=NC(=O)CN1\N=C\C1=CC=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 KSRLIXGNPXAZHD-HAZZGOGXSA-M 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000005495 thyroid hormone Substances 0.000 claims 1
- 229940036555 thyroid hormone Drugs 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97862607P | 2007-10-09 | 2007-10-09 | |
| US60/978,626 | 2007-10-09 | ||
| PCT/US2008/075406 WO2009048698A1 (en) | 2007-10-09 | 2008-09-05 | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500570A JP2011500570A (ja) | 2011-01-06 |
| JP2011500570A5 true JP2011500570A5 (Direct) | 2011-02-17 |
| JP5406197B2 JP5406197B2 (ja) | 2014-02-05 |
Family
ID=40316940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528917A Active JP5406197B2 (ja) | 2007-10-09 | 2008-09-05 | ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8975284B2 (Direct) |
| EP (2) | EP2219605B1 (Direct) |
| JP (1) | JP5406197B2 (Direct) |
| CA (1) | CA2702243C (Direct) |
| ES (1) | ES2583804T3 (Direct) |
| WO (1) | WO2009048698A1 (Direct) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080098614A1 (en) * | 2006-10-03 | 2008-05-01 | Wyeth | Lyophilization methods and apparatuses |
| WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
| US20120040970A1 (en) * | 2009-04-27 | 2012-02-16 | Al-Ghananeem Abeer M | Intranasal delivery system for dantrolene |
| US20140072525A1 (en) * | 2012-09-07 | 2014-03-13 | Gaab, Llc | Antimicrobial preparation and methods for making and using the same |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| JP2016514685A (ja) * | 2013-03-15 | 2016-05-23 | ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス | 異常レベルのカルシウム放出からリアノジン受容体を安定化するための化合物 |
| WO2015157212A1 (en) * | 2014-04-10 | 2015-10-15 | Us Worldmeds, Llc | Stable apomorphine composition and uses thereof |
| PL3364947T3 (pl) * | 2015-10-20 | 2022-02-07 | B. Braun Melsungen Ag | Wodna kompozycja zawierająca dantrolen |
| CA3067457A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Targeted therapeutics |
| SG11202003452XA (en) | 2017-10-20 | 2020-05-28 | Eagle Res Labs Limited | Dantrolene prodrugs and methods of their use |
| WO2019175761A1 (en) * | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
| TW202011940A (zh) * | 2018-04-05 | 2020-04-01 | 美商塔維達治療公司 | 具有降低量的三級丁醇之藥學組成物 |
| JPWO2020049670A1 (ja) * | 2018-09-06 | 2021-08-12 | シミックホールディングス株式会社 | ダントロレン水性製剤及びその調製方法 |
| WO2020112932A1 (en) * | 2018-11-27 | 2020-06-04 | Eagle Pharmaceuticals, Inc. | Use of dantrolene and dantrolene prodrugs to treat radiation exposure |
| WO2022169582A1 (en) * | 2021-02-05 | 2022-08-11 | Uswm, Llc | Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) * | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4543359A (en) | 1982-10-01 | 1985-09-24 | Eaton Laboratories, Inc. | Treating cardiac arrhythmias with dantrolene sodium |
| US5145769A (en) | 1987-08-21 | 1992-09-08 | Cryolife Inc. | Method for cryopreserving blood vessels |
| US5149621A (en) * | 1987-08-21 | 1992-09-22 | Cryolife, Inc. & Medical Univ. Of South Carolina | Kit for cryopreserving blood vessels |
| US5158867A (en) | 1987-08-21 | 1992-10-27 | Cryolife Inc. | Method for cryopreserving blood vessels |
| JPH01128923A (ja) * | 1987-11-11 | 1989-05-22 | Mikasa Seiyaku Kk | 骨格筋弛緩外用剤 |
| US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| WO1994005287A1 (en) * | 1992-09-09 | 1994-03-17 | Washington University | Prevention or treatment of sepsis with dantrolene or azumolene |
| JPH06263636A (ja) * | 1993-03-12 | 1994-09-20 | Kiyoshi Kataoka | 脳または高次神経疾患治療剤 |
| DE69528165T2 (de) | 1994-04-21 | 2003-05-15 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel |
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1435781A4 (en) * | 2001-06-23 | 2007-06-20 | Lyotropic Therapeutics Llc | SOLVENT SYSTEM |
| SI1603513T1 (sl) * | 2003-03-04 | 2021-04-30 | Lyotropic Therapeutics, Inc. | Sestavki dantrolena |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
-
2008
- 2008-09-05 EP EP08837079.6A patent/EP2219605B1/en active Active
- 2008-09-05 JP JP2010528917A patent/JP5406197B2/ja active Active
- 2008-09-05 US US12/205,303 patent/US8975284B2/en active Active
- 2008-09-05 ES ES08837079.6T patent/ES2583804T3/es active Active
- 2008-09-05 CA CA2702243A patent/CA2702243C/en active Active
- 2008-09-05 WO PCT/US2008/075406 patent/WO2009048698A1/en not_active Ceased
- 2008-09-05 EP EP12187466.3A patent/EP2583670A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103118662B (zh) | 制备冻干速溶多相剂型的方法 | |
| WO2009048698A4 (en) | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents | |
| CN109431966B (zh) | 依达拉奉药物组合物 | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| JP2023553976A5 (Direct) | ||
| JP2024522817A (ja) | フェニルピロールアミノグアニジン塩及び製剤 | |
| CN101784263A (zh) | 奈韦拉平的延长释放制剂 | |
| JPWO1995015751A1 (ja) | 解熱鎮痛配合剤 | |
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| CN102670577A (zh) | 一种光敏剂组合物、其使用方法及用途 | |
| TWI910222B (zh) | 為單片基質錠劑形式之控釋型含瑞巴派特醫藥組成物及其製備方法 | |
| TW202341973A (zh) | 治療性化合物、調配物、及其用途 | |
| CN103153306A (zh) | 三唑化合物的固体分散体 | |
| CN102933213A (zh) | 放射增敏剂组合物 | |
| ES2401992T3 (es) | Dispersión sólida estable de un derviado de alcaloide de vinca y procedimiento para su preparación | |
| CN102743384B (zh) | 一种含有西他沙星的药物组合物 | |
| CN101087591B (zh) | 长春花生物碱衍生物的稳定的固体分散体及其制备方法 | |
| JP2017502015A (ja) | 乾燥注腸製品 | |
| WO2025026423A1 (en) | Compositions, their use and manufacture for treatment of gastrointestinal conditions | |
| CN102552140A (zh) | 罗格列酮的液体组合物 | |
| CN100363001C (zh) | 一种莫西沙星胶囊剂及其制备方法 | |
| CN101921264A (zh) | 坎地沙坦有机胺盐及其制备方法和用途 | |
| US9717678B2 (en) | Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts | |
| CN104427971B (zh) | 乳头瘤病毒抑制剂的药物组合物 | |
| CN101322686A (zh) | 磺胺间甲氧嘧啶（钠）混悬注射液及其制备方法 |